377 related articles for article (PubMed ID: 17975523)
1. A once-yearly IV bisphosphonate for osteoporosis.
Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
[No Abstract] [Full Text] [Related]
2. Annual zoledronic acid for osteoporosis.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
[TBL] [Abstract][Full Text] [Related]
3. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
4. A once-yearly IV bisphosphonate for osteoporosis.
Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761
[No Abstract] [Full Text] [Related]
5. [Osteoporosis and bisphosphonates].
Zuber MA
Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
[No Abstract] [Full Text] [Related]
6. Yearly zoledronic acid in postmenopausal osteoporosis.
Chang JT
N Engl J Med; 2007 Aug; 357(7):713-4; author reply 714-5. PubMed ID: 17703528
[No Abstract] [Full Text] [Related]
7. Bisphosphonates: a once-yearly treatment option with Reclast.
Van Gilder D
S D Med; 2008 Nov; 61(11):416-7. PubMed ID: 19066136
[No Abstract] [Full Text] [Related]
8. Yearly zoledronic acid in postmenopausal osteoporosis.
de Nijs RN; Westgeest AA
N Engl J Med; 2007 Aug; 357(7):711; author reply 714-5. PubMed ID: 17699824
[No Abstract] [Full Text] [Related]
9. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
[TBL] [Abstract][Full Text] [Related]
10. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169
[No Abstract] [Full Text] [Related]
11. Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women.
Lafage-Proust MH
Kidney Int; 2008 Sep; 74(5):557-9. PubMed ID: 18709026
[TBL] [Abstract][Full Text] [Related]
12. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.
Med Lett Drugs Ther; 2009 Jun; 51(1315):49. PubMed ID: 19556940
[No Abstract] [Full Text] [Related]
13. Consultation corner. Bone loss drug gives users a break.
Bellantoni M
Johns Hopkins Med Lett Health After 50; 2007 Dec; 19(10):6. PubMed ID: 18225340
[No Abstract] [Full Text] [Related]
14. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Ringe JD
MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
[No Abstract] [Full Text] [Related]
15. Zoledronic acid: a review of its use in the treatment of osteoporosis.
Deeks ED; Perry CM
Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
[TBL] [Abstract][Full Text] [Related]
16. By the way, doctor. Should I take an intravenous drug for osteoporosis?
Robb-Nicholson C
Harv Womens Health Watch; 2007 Jul; 14(11):8. PubMed ID: 17665505
[No Abstract] [Full Text] [Related]
17. Yearly zoledronic acid in postmenopausal osteoporosis.
Poole KE; Kaptoge S; Reeve J
N Engl J Med; 2007 Aug; 357(7):711-2; author reply 714-5. PubMed ID: 17703530
[No Abstract] [Full Text] [Related]
18. What do we know about the ocular adverse effects associated with intravenous bisphosphonates?
Atik OS
Eklem Hastalik Cerrahisi; 2011; 22(1):1. PubMed ID: 21417978
[No Abstract] [Full Text] [Related]
19. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.
Lambrinoudaki I; Vlachou S; Galapi F; Papadimitriou D; Papadias K
Clin Interv Aging; 2008; 3(3):445-51. PubMed ID: 18982915
[TBL] [Abstract][Full Text] [Related]
20. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
Soen S
Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
